Premium
SOX ‐10 expression in cutaneous myoepitheliomas and mixed tumors
Author(s) -
Naujokas Agne,
CharliJoseph Yann,
Ruben Beth S.,
Yeh Iwei,
LeBoit Philip E.,
McCalmont Timothy H.,
Pincus Laura B.
Publication year - 2014
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12279
Subject(s) - pathology , immunohistochemistry , expression (computer science) , medicine , biology , computer science , programming language
Background SOX ‐10 expression can be demonstrated by immunohistochemistry in salivary gland myoepitheliomas, but its expression in cutaneous myoepitheliomas and in cutaneous mixed tumors with prominent myoepithelial cells has not been studied. Methods We assessed the staining pattern of SOX ‐10 in five cutaneous myoepitheliomas and six cutaneous mixed tumors with a prominent myoepithelial component among both the myoepithelial cells and cells lining lumens. In addition, we examined the staining of S100 , microphthalmia‐associated transcription factor ( MiTF ), keratin cocktail, HMK903 , smooth muscle actin ( SMA ) and epithelial membrane antigen ( EMA ). Results SOX ‐10 positivity was seen in three of five (60%) cutaneous myoepitheliomas and in the myoepithelial cells of all cutaneous mixed tumors. SOX ‐10 expression on the cells lining the glandular structures in mixed tumors was variable. All myoepitheliomas and mixed tumors stained positively with S100 and negatively with MiTF . Pan‐keratin, HMK903 , SMA and EMA showed variable expression. Conclusions SOX ‐10 is a relatively reliable marker for staining cutaneous myoepitheliomas. Cutaneous myoepitheliomas are notoriously difficult to diagnose, and the addition of SOX ‐10 to the repertoire of stains that can label this tumor is of practical utility. These results further support that cutaneous myoepitheliomas and cutaneous mixed tumors exist on a morphologic and immunophenotypic spectrum.